April 25, 2024
Bio
Samsung Biologics signs W306b contract with Cilag
[THE INVESTOR] Samsung Biologics announced on Nov. 16 that it has signed a 306.6 billion won (US$261.60 million) contract with Cilag GmbH International to produce drugs on consignment.
This amounts to 335.94 percent of its revenue in 2015.
This amounts to 335.94 percent of its revenue in 2015.
 |
The contract amount is based on the minimum amount of purchase and can increase upon negotiation. The contract period will remain undisclosed till Dec. 31, 2019 to protect trade secrets, said the company.
Cilag is a Swiss-based pharmaceutical subsidiary of multinational health care group Johnson & Johnson.
By Hwang You-mee (glamazon@heraldcorp.com)
![[From the Scene] KG Mobility poised to take next leap](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/24/20240424050621_0.jpg)
